You have not yet registered? Get your account for free.
Forgot Password? We will send you a reset link
30 April 2024
Newron announces positive top-line results from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients
Newron: Positive Topline-Ergebnisse der potenziell zulassungsrelevanten Phase-II/III-Studie 008A mit Evenamide in Schizophrenie-Patienten
17 April 2024
Newron vermeldet die Resultate der Generalversammlung 2024
8 April 2024
Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)
19 March 2024
Newron presents 2023 financial results and provides 2024 outlook
Newron gibt Geschäftsergebnisse 2023 und Ausblick 2024 bekannt